Daclizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Trial Timeline
Apr 1, 1999 → Dec 1, 2004
NCT ID
NCT00363116About Daclizumab
Daclizumab is a approved stage product being developed by Roche for Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT00363116. Target conditions include Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00284531 | Phase 1/2 | Terminated |
| NCT00231764 | Approved | Completed |
| NCT00363116 | Approved | Completed |
Competing Products
20 competing products in Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients